Only 3-antigen Hepatitis B Vaccine Expands Distribution

VBI Vaccines Inc. today announced the expansion of its 3-antigen hepatitis B vaccine and increased sales. PreHevbrio™ is the only 3-antigen hepatitis B vaccine available as of May 15, 2023, comprised of the three surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2.

This innovative vaccine is approved for use in the U.S., European Union/European Economic Area, United Kingdom, Canada, and Israel under the brand names PreHevbrio™ (U.S./Canada), PreHevbri® (EU/EEA/UK), and Sci-B-Vac® (Israel).

In the U.S., PreHevbrio is now available for purchase at six retail pharmacy chains, including Costco, RiteAid, Walmart, and three of the top 10 regional retail pharmacy networks, as well as through the U.S. Department of Veterans Affairs, Federal Bureau of Prisons, and at certain military treatment facilities.

PreHevbrio increased the total number of customer orders in Q1 2023 by 170% compared to Q4 2022.

In a press release, Jeff Baxter, VBI's President, and CEO, commented, "We continue to make good progress across all three endeavors, and I am especially excited to note the increase in the use of PreHevbrio in the U.S."

"With an ever-expanding access and distribution network in place and our focus on commercial execution, we expect to see this momentum continue throughout 2023 and beyond."

Furthermore, the Fance-based specialty vaccine company Valneva SE distributes PreHevbri throughout select European countries, which includes the United Kingdom, Sweden, Norway, Denmark, Finland, Belgium, and the Netherlands.